Neuromodulation for a Novel OCD Biomarker and Treatment
NCT: NCT05994053 · RECRUITING
Brief Summary
Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.
Frequently Asked Questions
What is Neuromodulation for a Novel OCD Biomarker and Treatment?
Neuromodulation for a Novel OCD Biomarker and Treatment is a clinical trial registered under NCT05994053. Current status: RECRUITING.
What is the status of NCT05994053?
The current status of NCT05994053 (Neuromodulation for a Novel OCD Biomarker and Treatment) is: RECRUITING.
When did Neuromodulation for a Novel OCD Biomarker and Treatment start?
Neuromodulation for a Novel OCD Biomarker and Treatment started on 2024-07-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.